Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIONEXT LABS LTD currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is handled by 1 distinct examiner and 1 distinct art unit. RONEY, CELESTE A is the busiest examiner, with 1 busiest examiner pending action.
The company's current activity in Biotechnology & Pharmaceuticals is concentrated under 1 distinct examiner. Because RONEY, CELESTE A is responsible for the 1 pending office action, the company's immediate prosecution strategy is focused on addressing the requirements of this specific examiner within the single identified art unit. For a practitioner, this means that the 1 busiest examiner pending action is the only active matter requiring attention. The outcome of this case will significantly influence the company's standing in the Biotechnology & Pharmaceuticals field. A successful resolution with RONEY, CELESTE A is necessary to advance the portfolio, as there are no other pending actions currently providing additional opportunities for patent grants within the 1 distinct art unit. The 1 pending office action is the central focus.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556171 | Antiviral compositions comprising liposome-encapsulated ascorbyl glucoside and natural extracts | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556171 | Antiviral compositions comprising liposome-encapsulated ascorbyl glucoside and natural extracts | RONEY, CELESTE A | 1612 | §112 | Non-Final OA | — | Pending | Oct 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIONEXT LABS LTD has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Celeste A Roney has the most, with 1 of BIONEXT LABS LTD's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
